There is compelling preclinical and clinical evidence to indicate that dysregulation of P-gp at the BBB contributes to the pathogenesis of neurodegenerative diseases, including Alzheimer’s disease (AD) [14,15,16,17]. This evidence concerns the gene PGP and early-onset autosomal dominant Alzheimer disease.